Pay in 4 interest-free payments of $5.73 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The latest results from the 2023 TEXAIS trial indicated that the use of exenatide (5 g, twice daily injections for 5 days) did not significantly reduce neurological damage within 7 days in patients with acute ischemic stroke (trial registration numbers: ACTRN12617000409370 and NCT03287076)
This peptide has quickly gained attention in regenerative medicineand for good reason
This finding raises the possibility of an important role of antioxidant function in modulating lifespan
Subsequently, the RAW264.7 cells were washed with PBS and stained by Ca 2+ Probe Fluo-4 AM for 20 min
We understand that timing and product integrity are critical for research
US$ 21.46
US$ 22.11
US$ 26.91
US$ 26.88
US$ 29.71
